^
7ms
Trial completion date • Metastases
|
paclitaxel • cixutumumab (IMC A12)
almost3years
Phase classification
|
EGFR (Epidermal growth factor receptor)
|
erlotinib • gemcitabine • cixutumumab (IMC A12)
over3years
Clinical • P2 data • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
Herceptin (trastuzumab) • lapatinib • capecitabine • cixutumumab (IMC A12)
over3years
The Immunotherapy Landscape in Adrenocortical Cancer. (PubMed, Cancers (Basel))
Immunotherapies that have been evaluated in clinical trials for ACC include the immune checkpoint inhibitors pembrolizumab, nivolumab, and avelumab. Other immunotherapies that have been evaluated include the monoclonal antibodies figitumumab and cixutumumab directed against the ACC-expressed insulin-like growth factor 1 (IGF-1) receptor, the recombinant cytotoxin interleukin-13-pseudomonas exotoxin A, and autologous tumor lysate dendritic cell vaccine. These agents have shown modest clinical activity, although nonzero in the case of the immune checkpoint inhibitors. Clinical trials are ongoing to evaluate whether this clinical activity may be augmented through combinations with other immune-acting agents or targeted therapies.
Review • Journal
|
IGF1 (Insulin-like growth factor 1)
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Bavencio (avelumab) • figitumumab (CP-751,871) • cixutumumab (IMC A12)
over4years
111In and 225Ac-labeled cixutumumab for imaging and alpha particle radiotherapy of IGF-1R positive triple negative breast cancer. (PubMed, Mol Pharm)
Additionally, low specific activity radioimmunoconjugate led to complete tumor remission in 2/6 mice. The data suggest that efficacy of cixutumumab can be enhanced by radiolabeling with 225Ac at a low specific activity.
Journal
|
IGF1R (Insulin-like growth factor 1 receptor)
|
IGF1R overexpression
|
cixutumumab (IMC A12)
over4years
The Receptor Tyrosine Kinase RON and Its Isoforms as Therapeutic Targets in Ewing Sarcoma. (PubMed, Cancers (Basel))
To examine RON-IGF1R crosstalk, we employed the clinical-grade monoclonal antibody IMC-RON8, alone and together with the IGF1R-antibody IMC-A12...Thus, this first report supports a role for RON in the metastatic progression of Ewing sarcoma. While principal molecular functions appear transferrable between carcinomas, Ewing sarcoma and possibly more common sarcoma subtypes, RON highlights that specific regulations of cellular networks and isoforms require better understanding to successfully transfer targeting strategies.
Journal
|
IGF1R (Insulin-like growth factor 1 receptor) • IGF1 (Insulin-like growth factor 1)
|
cixutumumab (IMC A12)
over4years
Clinical • Trial completion
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 amplification
|
Herceptin (trastuzumab) • lapatinib • capecitabine • cixutumumab (IMC A12)
over4years
Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer. (PubMed, Prostate Cancer Prostatic Dis)
In new metastatic hormone-sensitive prostate cancer, addition of cixutumumab to androgen deprivation did not improve survival. Baseline risk and disease volume carried prognostic value for this distinct trial population, although disease volume added more prognostic information. PSA treatment response was a strong intermediate endpoint for survival.
Clinical • P2 data • Journal
|
IGF1R (Insulin-like growth factor 1 receptor) • KLK3 (Kallikrein-related peptidase 3)
|
cixutumumab (IMC A12)
over4years
A Phase I Trial of IGF-1R Inhibitor Cixutumumab and mTOR Inhibitor Temsirolimus in Metastatic Castration-resistant Prostate Cancer. (PubMed, Clin Genitourin Cancer)
Despite a strong scientific rationale for the combination, temsirolimus plus cixutumumab demonstrated limited antitumor activity and a greater than expected incidence of toxicity, including low-grade pneumonitis and hyperglycemia. Hence, the trial was stopped in favor of alternative androgen receptor/phosphatidylinositol 3-kinase-directed combinatorial therapies.
P1 data • Journal
|
PTEN (Phosphatase and tensin homolog) • AR (Androgen receptor) • IGF1R (Insulin-like growth factor 1 receptor) • IGF1 (Insulin-like growth factor 1) • KLK3 (Kallikrein-related peptidase 3)
|
Torisel (temsirolimus) • cixutumumab (IMC A12)
almost5years
Survival outcomes and risk group validation from SWOG S0925, a randomized phase II study of androgen deprivation (AD) +/- cixutumumab, in new metastatic hormone-sensitive prostate cancer (mHSPC). (ASCO-GU 2020)
In new mHSPC, adding cixutumumab to AD did not improve survival measures. Baseline risk and disease volume carried prognostic value for this distinct trial population, though disease volume was a better predictor of survival. PSA treatment response was a strong intermediate endpoint for survival.
Clinical • P2 data
|
IGF1R (Insulin-like growth factor 1 receptor)
|
cixutumumab (IMC A12)
almost5years
Survival outcomes and risk group validation from SWOG S0925, a randomized phase II study of androgen deprivation (AD) +/- cixutumumab, in new metastatic hormone-sensitive prostate cancer (mHSPC). (ASCO-GU 2020)
In new mHSPC, adding cixutumumab to AD did not improve survival measures. Baseline risk and disease volume carried prognostic value for this distinct trial population, though disease volume was a better predictor of survival. PSA treatment response was a strong intermediate endpoint for survival.
Clinical • P2 data
|
IGF1R (Insulin-like growth factor 1 receptor)
|
cixutumumab (IMC A12)